Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Market
0.0%
Details
- Resolved Date
- 11/15/24
- Study Completion
- 3/1/26
- Company
- Vir Biotechnology, Inc.
- Ticker
- VIR
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 244
- Volume
- $0
- NCT
- NCT04856085
- Drug Description
- This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Exact Phase 2 MARCH/NCT04856085 readout was publicly framed as positive by the sponsor: end-of-treatment results were labeled positive/encouraging, and the later post-treatment update said the study-defined primary endpoint was achieved. Evidence is trial-specific, not pooled.
Sources
Sponsorinvestors.vir.bio11/15/24
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study
For MARCH Phase 2, Vir said the study showed promising HBsAg loss, safety/efficacy supported continued development, and investigators called the end-of-treatment data encouraging.
View source
Sponsorinvestors.vir.bio5/9/25
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Vir reported that the study-defined primary endpoint was achieved at 24 weeks post-end of treatment in low-baseline-HBsAg participants, with no new safety concerns.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
